These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 32737994)

  • 21. Oesophageal cancer.
    Smyth EC; Lagergren J; Fitzgerald RC; Lordick F; Shah MA; Lagergren P; Cunningham D
    Nat Rev Dis Primers; 2017 Jul; 3():17048. PubMed ID: 28748917
    [TBL] [Abstract][Full Text] [Related]  

  • 22. ERBB2 amplifications in esophageal adenocarcinoma.
    Dahlberg PS; Jacobson BA; Dahal G; Fink JM; Kratzke RA; Maddaus MA; Ferrin LJ
    Ann Thorac Surg; 2004 Nov; 78(5):1790-800. PubMed ID: 15511476
    [TBL] [Abstract][Full Text] [Related]  

  • 23. circCDYL2 promotes trastuzumab resistance via sustaining HER2 downstream signaling in breast cancer.
    Ling Y; Liang G; Lin Q; Fang X; Luo Q; Cen Y; Mehrpour M; Hamai A; Liu Z; Shi Y; Li J; Lin W; Jia S; Yang W; Liu Q; Song E; Li J; Gong C
    Mol Cancer; 2022 Jan; 21(1):8. PubMed ID: 34980129
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lapatinib versus lapatinib plus capecitabine as second-line treatment in human epidermal growth factor receptor 2-amplified metastatic gastro-oesophageal cancer: a randomised phase II trial of the Arbeitsgemeinschaft Internistische Onkologie.
    Lorenzen S; Riera Knorrenschild J; Haag GM; Pohl M; Thuss-Patience P; Bassermann F; Helbig U; Weißinger F; Schnoy E; Becker K; Stocker G; Rüschoff J; Eisenmenger A; Karapanagiotou-Schenkel I; Lordick F
    Eur J Cancer; 2015 Mar; 51(5):569-76. PubMed ID: 25694417
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Knockdown of Grb7 inhibits growth of oral squamous cell carcinoma, cell proliferation and promoted apoptosis through ERK/FOXM1 pathway].
    Liu BY; Cao G; Dong Z; Chen W; Xu JK; Zhang SL; Weng ZQ
    Shanghai Kou Qiang Yi Xue; 2016 Dec; 25(6):688-693. PubMed ID: 28275791
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gasdermin B expression predicts poor clinical outcome in HER2-positive breast cancer.
    Hergueta-Redondo M; Sarrio D; Molina-Crespo Á; Vicario R; Bernadó-Morales C; Martínez L; Rojo-Sebastián A; Serra-Musach J; Mota A; Martínez-Ramírez Á; Castilla MÁ; González-Martin A; Pernas S; Cano A; Cortes J; Nuciforo PG; Peg V; Palacios J; Pujana MÁ; Arribas J; Moreno-Bueno G
    Oncotarget; 2016 Aug; 7(35):56295-56308. PubMed ID: 27462779
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Specific peptide ligand for Grb7 signal transduction protein and pancreatic cancer metastasis.
    Tanaka S; Pero SC; Taguchi K; Shimada M; Mori M; Krag DN; Arii S
    J Natl Cancer Inst; 2006 Apr; 98(7):491-8. PubMed ID: 16595785
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Re-evaluation of HER2 status in patients with HER2-positive advanced or recurrent gastric cancer refractory to trastuzumab (KSCC1604).
    Saeki H; Oki E; Kashiwada T; Arigami T; Makiyama A; Iwatsuki M; Narita Y; Satake H; Matsuda Y; Sonoda H; Shimokawa M; Maehara Y;
    Eur J Cancer; 2018 Dec; 105():41-49. PubMed ID: 30391779
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Growth factor receptor bound protein-7 regulates proliferation, cell cycle, and mitochondrial apoptosis of thyroid cancer cells via MAPK/ERK signaling.
    Tang H; Yang P; Yang X; Peng S; Hu X; Bao G
    Mol Cell Biochem; 2020 Sep; 472(1-2):209-218. PubMed ID: 32577949
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Coamplification and coexpression of GRB7 and ERBB2 is found in high grade intraepithelial neoplasia and in invasive Barrett's carcinoma.
    Walch A; Specht K; Braselmann H; Stein H; Siewert JR; Hopt U; Höfler H; Werner M
    Int J Cancer; 2004 Dec; 112(5):747-53. PubMed ID: 15386389
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study.
    Doi T; Shitara K; Naito Y; Shimomura A; Fujiwara Y; Yonemori K; Shimizu C; Shimoi T; Kuboki Y; Matsubara N; Kitano A; Jikoh T; Lee C; Fujisaki Y; Ogitani Y; Yver A; Tamura K
    Lancet Oncol; 2017 Nov; 18(11):1512-1522. PubMed ID: 29037983
    [TBL] [Abstract][Full Text] [Related]  

  • 32. EGFR, HER2 and HER3 dimerization patterns guide targeted inhibition in two histotypes of esophageal cancer.
    Fichter CD; Timme S; Braun JA; Gudernatsch V; Schöpflin A; Bogatyreva L; Geddert H; Faller G; Klimstra D; Tang L; Hauschke D; Werner M; Lassmann S
    Int J Cancer; 2014 Oct; 135(7):1517-30. PubMed ID: 24510732
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Concurrent biological targeting therapy of squamous cell carcinoma of the esophagus with cetuximab and trastuzumab.
    Yamazaki M; Yamashita Y; Kubo N; Yashiro M; Ohira M; Ako E; Tanaka H; Muguruma K; Sawada T; Hirakawa K
    Oncol Rep; 2012 Jul; 28(1):49-54. PubMed ID: 22562413
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Assessment of HER2 status in patients with gastroesophageal adenocarcinoma treated with epirubicin-based chemotherapy: heterogeneity-related issues and prognostic implications.
    Personeni N; Baretti M; Bozzarelli S; Spaggiari P; Rubino L; Tronconi MC; Fumagalli Romario U; Rosati R; Giordano L; Roncalli M; Santoro A; Rimassa L
    Gastric Cancer; 2017 May; 20(3):428-437. PubMed ID: 27530622
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Grb7, a Critical Mediator of EGFR/ErbB Signaling, in Cancer Development and as a Potential Therapeutic Target.
    Chu PY; Tai YL; Shen TL
    Cells; 2019 May; 8(5):. PubMed ID: 31083325
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Expression of HER2 and the coamplified genes GRB7 and MLN64 in human breast cancer: quantitative real-time reverse transcription-PCR as a diagnostic alternative to immunohistochemistry and fluorescence in situ hybridization.
    Vinatzer U; Dampier B; Streubel B; Pacher M; Seewald MJ; Stratowa C; Kaserer K; Schreiber M
    Clin Cancer Res; 2005 Dec; 11(23):8348-57. PubMed ID: 16322295
    [TBL] [Abstract][Full Text] [Related]  

  • 37. HER2-Targeted PET Imaging and Therapy of Hyaluronan-Masked HER2-Overexpressing Breast Cancer.
    Pereira PMR; Ragupathi A; Shmuel S; Mandleywala K; Viola NT; Lewis JS
    Mol Pharm; 2020 Jan; 17(1):327-337. PubMed ID: 31804840
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase I/II study of trastuzumab, paclitaxel, cisplatin and radiation for locally advanced, HER2 overexpressing, esophageal adenocarcinoma.
    Safran H; Dipetrillo T; Akerman P; Ng T; Evans D; Steinhoff M; Benton D; Purviance J; Goldstein L; Tantravahi U; Kennedy T
    Int J Radiat Oncol Biol Phys; 2007 Feb; 67(2):405-9. PubMed ID: 17097832
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of growth factor receptor bound protein 7 in hepatocellular carcinoma.
    Itoh S; Taketomi A; Tanaka S; Harimoto N; Yamashita Y; Aishima S; Maeda T; Shirabe K; Shimada M; Maehara Y
    Mol Cancer Res; 2007 Jul; 5(7):667-73. PubMed ID: 17634422
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeted therapy for upper gastrointestinal tract cancer: current and future prospects.
    Rosenbaum MW; Gonzalez RS
    Histopathology; 2021 Jan; 78(1):148-161. PubMed ID: 33382497
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.